Literature DB >> 26283479

The Presence and Preferential Activation of Regulatory T Cells Diminish Adoptive Transfer of Autoimmune Diabetes by Polyclonal Nonobese Diabetic (NOD) T Cell Effectors into NSG versus NOD-scid Mice.

Maximiliano Presa1, Yi-Guang Chen2, Alexandra E Grier1, Edward H Leiter1, Michael A Brehm3, Dale L Greiner3, Leonard D Shultz1, David V Serreze4.   

Abstract

NOD-scid.Il2rg(null) (NSG) mice are currently being used as recipients to screen for pathogenic autoreactive T cells in type 1 diabetes (T1D) patients. We questioned whether the restriction of IL-2R γ-chain (Il-2rγ)-dependent cytokine signaling only to donor cells in NSG recipients differently influenced the activities of transferred diabetogenic T cells when they were introduced as a monoclonal/oligoclonal population versus being part of a polyclonal repertoire. Unexpectedly, a significantly decreased T1D transfer by splenocytes from prediabetic NOD donors was observed in Il-2rγ(null)-NSG versus Il-2rγ-intact standard NOD-scid recipients. In contrast, NOD-derived monoclonal/oligoclonal TCR transgenic β cell-autoreactive T cells in either the CD8 (AI4, NY8.3) or CD4 (BDC2.5) compartments transferred disease significantly more rapidly to NSG than to NOD-scid recipients. The reduced diabetes transfer efficiency by polyclonal T cells in NSG recipients was associated with enhanced activation of regulatory T cells (Tregs) mediated by NSG myeloid APC. This enhanced suppressor activity was associated with higher levels of Treg GITR expression in the presence of NSG than NOD-scid APC. These collective results indicate NSG recipients might be efficiently employed to test the activity of T1D patient-derived β cell-autoreactive T cell clones and lines, but, when screening for pathogenic effectors within polyclonal populations, Tregs should be removed from the transfer inoculum to avoid false-negative results.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26283479      PMCID: PMC4575869          DOI: 10.4049/jimmunol.1402446

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  30 in total

1.  Humanized mice as a preclinical tool for infectious disease and biomedical research.

Authors:  Leonard D Shultz; Michael A Brehm; Sina Bavari; Dale L Greiner
Journal:  Ann N Y Acad Sci       Date:  2011-12       Impact factor: 5.691

Review 2.  Humanized mice for immune system investigation: progress, promise and challenges.

Authors:  Leonard D Shultz; Michael A Brehm; J Victor Garcia-Martinez; Dale L Greiner
Journal:  Nat Rev Immunol       Date:  2012-10-12       Impact factor: 53.106

3.  NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells.

Authors:  Mamoru Ito; Hidefumi Hiramatsu; Kimio Kobayashi; Kazutomo Suzue; Mariko Kawahata; Kyoji Hioki; Yoshito Ueyama; Yoshio Koyanagi; Kazuo Sugamura; Kohichiro Tsuji; Toshio Heike; Tatsutoshi Nakahata
Journal:  Blood       Date:  2002-11-01       Impact factor: 22.113

4.  Immunostimulation circumvents diabetes in NOD/Lt mice.

Authors:  D V Serreze; K Hamaguchi; E H Leiter
Journal:  J Autoimmun       Date:  1989-12       Impact factor: 7.094

5.  An early age-related increase in the frequency of CD4+ Foxp3+ cells in BDC2.5NOD mice.

Authors:  David C Thomas; Richard J Mellanby; Jenny M Phillips; Anne Cooke
Journal:  Immunology       Date:  2007-04-16       Impact factor: 7.397

6.  Identification of a CD8 T cell that can independently mediate autoimmune diabetes development in the complete absence of CD4 T cell helper functions.

Authors:  R T Graser; T P DiLorenzo; F Wang; G J Christianson; H D Chapman; D C Roopenian; S G Nathenson; D V Serreze
Journal:  J Immunol       Date:  2000-04-01       Impact factor: 5.422

Review 7.  Development of monocytes, macrophages, and dendritic cells.

Authors:  Frederic Geissmann; Markus G Manz; Steffen Jung; Michael H Sieweke; Miriam Merad; Klaus Ley
Journal:  Science       Date:  2010-02-05       Impact factor: 47.728

8.  A recombinant heavy chain antibody approach blocks ART2 mediated deletion of an iNKT cell population that upon activation inhibits autoimmune diabetes.

Authors:  Felix Scheuplein; Björn Rissiek; John P Driver; Yi-Guang Chen; Friedrich Koch-Nolte; David V Serreze
Journal:  J Autoimmun       Date:  2009-10-01       Impact factor: 7.094

9.  IL-15 Fosters Age-Driven Regulatory T Cell Accrual in the Face of Declining IL-2 Levels.

Authors:  Jana Raynor; Allyson Sholl; David R Plas; Philippe Bouillet; Claire A Chougnet; David A Hildeman
Journal:  Front Immunol       Date:  2013-06-24       Impact factor: 7.561

10.  IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells.

Authors:  Yenkel Grinberg-Bleyer; Audrey Baeyens; Sylvaine You; Rima Elhage; Gwladys Fourcade; Sylvie Gregoire; Nicolas Cagnard; Wassila Carpentier; Qizhi Tang; Jeffrey Bluestone; Lucienne Chatenoud; David Klatzmann; Benoît L Salomon; Eliane Piaggio
Journal:  J Exp Med       Date:  2010-08-02       Impact factor: 14.307

View more
  9 in total

Review 1.  Tolerogenic Nanoparticles to Treat Islet Autoimmunity.

Authors:  Tobias Neef; Stephen D Miller
Journal:  Curr Diab Rep       Date:  2017-08-08       Impact factor: 4.810

2.  Nfkbid Overexpression in Nonobese Diabetic Mice Elicits Complete Type 1 Diabetes Resistance in Part Associated with Enhanced Thymic Deletion of Pathogenic CD8 T Cells and Increased Numbers and Activity of Regulatory T Cells.

Authors:  Jennifer R Dwyer; Jeremy J Racine; Harold D Chapman; Anna Quinlan; Maximiliano Presa; Grace A Stafford; Ingo Schmitz; David V Serreze
Journal:  J Immunol       Date:  2022-06-27       Impact factor: 5.426

3.  The CD137 Ligand Is Important for Type 1 Diabetes Development but Dispensable for the Homeostasis of Disease-Suppressive CD137+ FOXP3+ Regulatory CD4 T Cells.

Authors:  Bardees M Foda; Ashley E Ciecko; David V Serreze; William M Ridgway; Aron M Geurts; Yi-Guang Chen
Journal:  J Immunol       Date:  2020-04-15       Impact factor: 5.422

Review 4.  Humanized Mouse Models of Rheumatoid Arthritis for Studies on Immunopathogenesis and Preclinical Testing of Cell-Based Therapies.

Authors:  Katina Schinnerling; Carlos Rosas; Lilian Soto; Ranjeny Thomas; Juan Carlos Aguillón
Journal:  Front Immunol       Date:  2019-02-19       Impact factor: 7.561

Review 5.  Endogenous Pancreatic β Cell Regeneration: A Potential Strategy for the Recovery of β Cell Deficiency in Diabetes.

Authors:  Fan Zhong; Yan Jiang
Journal:  Front Endocrinol (Lausanne)       Date:  2019-02-20       Impact factor: 5.555

6.  Targeting transcriptional coregulator OCA-B/Pou2af1 blocks activated autoreactive T cells in the pancreas and type 1 diabetes.

Authors:  Heejoo Kim; Jelena Perovanovic; Arvind Shakya; Zuolian Shen; Cody N German; Andrea Ibarra; Jillian L Jafek; Nai-Pin Lin; Brian D Evavold; Danny H-C Chou; Peter E Jensen; Xiao He; Dean Tantin
Journal:  J Exp Med       Date:  2021-03-01       Impact factor: 14.307

7.  CD95/Fas protects triple negative breast cancer from anti-tumor activity of NK cells.

Authors:  Abdul S Qadir; Jean Philippe Guégan; Christophe Ginestier; Assia Chaibi; Alban Bessede; Emmanuelle Charafe-Jauffret; Manon Macario; Vincent Lavoué; Thibault de la Motte Rouge; Calvin Law; Jacob Vilker; Hongbin Wang; Emily Stroup; Matthew J Schipma; Bryan Bridgeman; Andrea E Murmann; Zhe Ji; Patrick Legembre; Marcus E Peter
Journal:  iScience       Date:  2021-10-29

8.  Fatty acid binding protein 4 promotes autoimmune diabetes by recruitment and activation of pancreatic islet macrophages.

Authors:  Yang Xiao; Lingling Shu; Xiaoping Wu; Yang Liu; Lai Yee Cheong; Boya Liao; Xiaoyu Xiao; Ruby Lc Hoo; Zhiguang Zhou; Aimin Xu
Journal:  JCI Insight       Date:  2021-04-08

9.  Proinsulin-specific T regulatory cells may control immune responses in type 1 diabetes: implications for adoptive therapy.

Authors:  Mateusz Gliwiński; Dorota Iwaszkiewicz-Grześ; Anna Wołoszyn-Durkiewicz; Monika Tarnowska; Magdalena Żalińska; Matylda Hennig; Hanna Zielińska; Anna Dukat-Mazurek; Joanna Zielkowska-Dębska; Maciej Zieliński; Anna Jaźwińska-Curyłło; Radosław Owczuk; Przemysława Jarosz-Chobot; Artur Bossowski; Agnieszka Szadkowska; Wojciech Młynarski; Natalia Marek-Trzonkowska; Grażyna Moszkowska; Janusz Siebert; Małgorzata Myśliwiec; Piotr Trzonkowski
Journal:  BMJ Open Diabetes Res Care       Date:  2020-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.